Exelixis
EXEL
33,84 €
Share price
1.79%
Change (1 day)
56.11%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
EPS for Exelixis (EXEL)
EPS in 2023 (TTM): 0,26 €
According to Exelixis's latest financial reports the company's current EPS (TTM) is 0,26 €. In 2022 the company made an earnings per share (EPS) of 0,52 € a decrease over its 2021 EPS that were of 0,68 €.
EPS history for Exelixis from 2000 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | 0,26 € | -50.2% |
| 2022 | 0,52 € | -22.97% |
| 2021 | 0,68 € | 100% |
| 2020 | 0,34 € | -65.09% |
| 2019 | 0,97 € | -53.91% |
| 2018 | 2,10 € | 333.96% |
| 2017 | 0,48 € | -260.61% |
| 2016 | -0,30 € | -58.75% |
| 2015 | -0,73 € | -42.45% |
| 2014 | -1,27 € | 5.3% |
| 2013 | -1,21 € | 43.48% |
| 2012 | -0,84 € | -264.29% |
| 2011 | 0,51 € | -165.88% |
| 2010 | -0,78 € | -32.54% |
| 2009 | -1,15 € | -17.65% |
| 2008 | -1,40 € | 75.86% |
| 2007 | -0,79 € | -25.64% |
| 2006 | -1,07 € | 8.33% |
| 2005 | -0,99 € | -42.86% |
| 2004 | -1,73 € | 30.34% |
| 2003 | -1,32 € | -5.23% |
| 2002 | -1,40 € | -0.65% |
| 2001 | -1,41 € | -51.88% |
| 2000 | -2,92 € |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 | 3,20 € | 1,135.69% | 🇬🇧 UK |
 | 2,91 € | 1,022.57% | 🇫🇷 France |
 | 1,66 € | 543.02% | 🇺🇸 USA |
 | 3,63 € | 1,301.34% | 🇺🇸 USA |
 | 12,93 € | 4,894.71% | 🇺🇸 USA |
 | 12,87 € | 4,871.87% | 🇺🇸 USA |
 | 1,70 € | 556.55% | 🇺🇸 USA |
 | -9,14 € | -3,629.83% | 🇺🇸 USA |
 | -0,77 € | -396.51% | 🇺🇸 USA |